Hybio Pharmaceutical(300199.SZ): Aselegine Injection approved for listing, used to improve blood sugar control in type 2 diabetes patients.
Han Yu Pharmaceutical (300199.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration...
Hybio Pharmaceutical (300199.SZ) announcement, recently, the company received the "Drug Registration Certificate" issued by the National Medical Products Administration, and the company's "exenatide injection" obtained drug registration approval. It is reported that exenatide is a glucagon-like peptide-1 (GLP-1) analog used to improve blood sugar control in patients with type 2 diabetes, suitable for patients who do not have adequate blood sugar control with metformin alone, sulfonylureas alone, or a combination of metformin and sulfonylureas.
Related Articles
UBS: Maintains "Buy" rating on ND PAPER (02689), target price HK$11.82, continues to expand pulp production capacity and resumes dividend payments.
As Nscale files, Bernstein takes the pulse of AI compute clouds: CoreWeave (CRWV.US) "underperforms the market," IREN (IREN.US) "outperforms the market"
CLSA: Maintains "Outperform" rating on JNBY (03306), target price HK$25, expects FY2027 sales and net profit to increase by 8% and 9% respectively.
UBS: Maintains "Buy" rating on ND PAPER (02689), target price HK$11.82, continues to expand pulp production capacity and resumes dividend payments.
As Nscale files, Bernstein takes the pulse of AI compute clouds: CoreWeave (CRWV.US) "underperforms the market," IREN (IREN.US) "outperforms the market"
CLSA: Maintains "Outperform" rating on JNBY (03306), target price HK$25, expects FY2027 sales and net profit to increase by 8% and 9% respectively.
